Profile
Terbium is a rare-earth metal remarkable in nuclear medicine for offering four medically useful radioisotopes of a single element. Terbium-149 is a synthetic radioisotope produced for targeted alpha therapy, with a half-life of about 4 hours.
Terbium-149 emits alpha particles, delivering intensely damaging radiation over a very short range that is highly effective at destroying targeted cancer cells. It is the only lanthanide alpha emitter of real clinical interest, allowing for highly stable binding and ability to bind to the same targeting molecules as established beta therapies using lutetium. Terbium-149 shares the chemistry of the imaging terbium isotopes, so it can be delivered and tracked using the same molecules.
Terbium-149 is among the most difficult medical isotopes to produce, requiring high-energy proton spallation or heavy-ion reactions followed by mass separation, currently achievable only at large research facilities and in very small quantities. This acute scarcity is the principal barrier to its clinical development.
StandardX’s accelerator-based production route makes it possible for this rare alpha emitter to become more widely accessible.